Global Bioengineered Protein Drugs Market: Industry Analysis and forecast (2019 to 2026): By Type, Disease Condition, and Region

Global Bioengineered Protein Drugs Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026. To know about the Research Methodology :- Request Free Sample Report

Global Bioengineered Protein Drugs Market Drivers and Restrains

Bioengineered proteins are designed as the fundamental participants in all biological processes, represent as powerful therapeutic proteins. These special drugs are gaining attention across pharmaceutical industries due to their specificity, safety, bio reactivity and success rate in treating life-threatening diseases and injuries. Bioengineered protein drugs are the major factors conducting the biological process and come up with the efficient therapeutic agents. The bioengineered protein drug includes wide-ranging products such as hormones, vaccines, cytokines, and monoclonal antibodies. Rising patient population with diseases such as cancer, heart diseases, diabetes, and asthma are fueling the global bioengineered protein drugs market. High manufacturing cost and Complications in treatment of numerous diseases with these drugs hamper growth of bioengineered protein drugs market globally. Furthermore, novel techniques in manufacturing of bioengineering drug proteins aimed at the specific drug delivery and drug combinations for increasing efficiency of product are the factors driving global market. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Bioengineered Protein Drugs Market key segmentation

Global Bioengineered Protein Drugs Market is segmented into type and Disease condition. Based on type market is further categorized as Monoclonal Antibodies, Therapeutic Proteins and Vaccines. Monoclonal Antibodies is further sub-divided in to Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, and Synazis. And Therapeutic Proteins segment into Hormones, Cytokines, Blood Factor, Enzyme Therapy, and Thrombolytic. Among them, the therapeutic protein segment leads with highest share of Global Bioengineered Protein Drugs Market in 2018. Because of extensive activities in the therapeutic protein engineering and recombinant DNA technology products.

Global Bioengineered Protein Drugs Market Regional Analysis

Based on region, the global bioengineered protein drugs market is divided into North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America dominated the Global Bioengineered Protein Drugs Market in 2018. Rising instances of cancer and emergence of innovative protein therapeutics for treatment of cancer are responsible for increased growth rate in this region. Europe holds 2nd highest share of global Bioengineered Protein Drugs market. Increased R&D spending, along with increasing competition, patent expiries and new technologies are the factors propelling global market in this region. Asia Pacific region is expected to register highest growth rate in the global bioengineered protein drug market owing to the factors such as developing economic market scenario and developing research sector. The objective of the report is to present comprehensive analysis of Global Bioengineered Protein Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Bioengineered Protein Drugs Market dynamics, structure by analyzing the market segments, and project the Global Bioengineered Protein Drugs Market size. Clear representation of competitive analysis of key players by Bioengineered Protein Drugs Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Bioengineered Protein Drugs Market make the report investor’s guide.

Scope for Global Bioengineered Protein Drugs Market: Inquire before buying

Global Bioengineered Protein Drugs Market by type

• Monoclonal Antibodies • Therapeutic Proteins • Vaccines

Global Bioengineered Protein Drugs Market by Disease Condition

• Cancer • Diabetes • Autoimmune Disorder • Infectious Disease • Hematopoiesis • CVD • Neurodegenerative

Global Bioengineered Protein Drugs Market by region

• Asia Pacific • North America • Europe • Latin America • Middle East Africa

Key players operating on Global Bioengineered Protein Drugs Market

• Abbott India Ltd.; • Amgen, Inc.; • Bayer AG; • Biocon Ltd.; • Dr. Reddy’s Laboratories Ltd.; • Eli Lilly and Company; • F. Hoffmann Roche AG; • GlaxoSmithKline PLC; • Johnson & Johnson; • Merck & Co., Inc.; • Novartis International AG; • Panacea Biotec Ltd.; • ProBioGen AG • Reliance Life Sciences Pvt. Ltd.,
Global Bioengineered Protein Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Bioengineered Protein Drugs Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Bioengineered Protein Drugs Market Analysis and Forecast 6.1. Global Bioengineered Protein Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Bioengineered Protein Drugs Market Analysis and Forecast, By Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Bioengineered Protein Drugs Market Value Share Analysis, By Type 7.4. Global Bioengineered Protein Drugs Market Size (US$ Bn) Forecast, By Type 7.5. Global Bioengineered Protein Drugs Market Analysis, By Type 7.6. Global Bioengineered Protein Drugs Market Attractiveness Analysis, By Type 8. Global Bioengineered Protein Drugs Market Analysis and Forecast, By Disease Condition 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Bioengineered Protein Drugs Market Value Share Analysis, By Disease Condition 8.4. Global Bioengineered Protein Drugs Market Size (US$ Bn) Forecast, By Disease Condition 8.5. Global Bioengineered Protein Drugs Market Analysis, By Disease Condition 8.6. Global Bioengineered Protein Drugs Market Attractiveness Analysis, By Disease Condition 9. Global Bioengineered Protein Drugs Market Analysis, by Region 9.1. Global Bioengineered Protein Drugs Market Value Share Analysis, by Region 9.2. Global Bioengineered Protein Drugs Market Size (US$ Bn) Forecast, by Region 9.3. Global Bioengineered Protein Drugs Market Attractiveness Analysis, by Region 10. North America Bioengineered Protein Drugs Market Analysis 10.1. Key Findings 10.2. North America Bioengineered Protein Drugs Market Overview 10.3. North America Bioengineered Protein Drugs Market Value Share Analysis, By Type 10.4. North America Bioengineered Protein Drugs Market Forecast, By Type 10.4.1. Monoclonal Antibodies 10.4.2. Therapeutic Proteins 10.4.3. Vaccines 10.5. North America Bioengineered Protein Drugs Market Value Share Analysis, By Disease Condition 10.6. North America Bioengineered Protein Drugs Market Forecast, By Disease Condition 10.6.1. Cancer 10.6.2. Diabetes 10.6.3. Autoimmune Disorder 10.6.4. Infectious Disease 10.6.5. Hematopoiesis 10.6.6. CVD 10.6.7. Neurodegenerative 10.7. North America Bioengineered Protein Drugs Market Value Share Analysis, by Country 10.8. North America Bioengineered Protein Drugs Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Bioengineered Protein Drugs Market Analysis, by Country 10.10. U.S. Bioengineered Protein Drugs Market Forecast, By Type 10.10.1. Monoclonal Antibodies 10.10.2. Therapeutic Proteins 10.10.3. Vaccines 10.11. U.S. Bioengineered Protein Drugs Market Forecast, By Disease Condition 10.11.1. Cancer 10.11.2. Diabetes 10.11.3. Autoimmune Disorder 10.11.4. Infectious Disease 10.11.5. Hematopoiesis 10.11.6. CVD 10.11.7. Neurodegenerative 10.12. Canada Bioengineered Protein Drugs Market Forecast, By Type 10.12.1. Monoclonal Antibodies 10.12.2. Therapeutic Proteins 10.12.3. Vaccines 10.13. Canada Bioengineered Protein Drugs Market Forecast, By Disease Condition 10.13.1. Cancer 10.13.2. Diabetes 10.13.3. Autoimmune Disorder 10.13.4. Infectious Disease 10.13.5. Hematopoiesis 10.13.6. CVD 10.13.7. Neurodegenerative 10.14. North America Bioengineered Protein Drugs Market Attractiveness Analysis 10.14.1. By Type 10.14.2. By Disease Condition 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Bioengineered Protein Drugs Market Analysis 11.1. Key Findings 11.2. Europe Bioengineered Protein Drugs Market Overview 11.3. Europe Bioengineered Protein Drugs Market Value Share Analysis, By Type 11.4. Europe Bioengineered Protein Drugs Market Forecast, By Type 11.4.1. Monoclonal Antibodies 11.4.2. Therapeutic Proteins 11.4.3. Vaccines 11.5. Europe Bioengineered Protein Drugs Market Value Share Analysis, By Disease Condition 11.6. Europe Bioengineered Protein Drugs Market Forecast, By Disease Condition 11.6.1. Cancer 11.6.2. Diabetes 11.6.3. Autoimmune Disorder 11.6.4. Infectious Disease 11.6.5. Hematopoiesis 11.6.6. CVD 11.6.7. Neurodegenerative 11.7. Europe Bioengineered Protein Drugs Market Value Share Analysis, by Country 11.8. Europe Bioengineered Protein Drugs Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Bioengineered Protein Drugs Market Analysis, by Country 11.10. Germany Bioengineered Protein Drugs Market Forecast, By Type 11.10.1. Monoclonal Antibodies 11.10.2. Therapeutic Proteins 11.10.3. Vaccines 11.11. Germany Bioengineered Protein Drugs Market Forecast, By Disease Condition 11.11.1. Cancer 11.11.2. Diabetes 11.11.3. Autoimmune Disorder 11.11.4. Infectious Disease 11.11.5. Hematopoiesis 11.11.6. CVD 11.11.7. Neurodegenerative 11.12. U.K. Bioengineered Protein Drugs Market Forecast, By Type 11.12.1. Monoclonal Antibodies 11.12.2. Therapeutic Proteins 11.12.3. Vaccines 11.13. U.K. Bioengineered Protein Drugs Market Forecast, By Disease Condition 11.13.1. Cancer 11.13.2. Diabetes 11.13.3. Autoimmune Disorder 11.13.4. Infectious Disease 11.13.5. Hematopoiesis 11.13.6. CVD 11.13.7. Neurodegenerative 11.14. France Bioengineered Protein Drugs Market Forecast, By Type 11.14.1. Monoclonal Antibodies 11.14.2. Therapeutic Proteins 11.14.3. Vaccines 11.15. France Bioengineered Protein Drugs Market Forecast, By Disease Condition 11.15.1. Cancer 11.15.2. Diabetes 11.15.3. Autoimmune Disorder 11.15.4. Infectious Disease 11.15.5. Hematopoiesis 11.15.6. CVD 11.15.7. Neurodegenerative 11.16. Italy Bioengineered Protein Drugs Market Forecast, By Type 11.16.1. Monoclonal Antibodies 11.16.2. Therapeutic Proteins 11.16.3. Vaccines 11.17. Italy Bioengineered Protein Drugs Market Forecast, By Disease Condition 11.17.1. Cancer 11.17.2. Diabetes 11.17.3. Autoimmune Disorder 11.17.4. Infectious Disease 11.17.5. Hematopoiesis 11.17.6. CVD 11.17.7. Neurodegenerative 11.18. Spain Bioengineered Protein Drugs Market Forecast, By Type 11.18.1. Monoclonal Antibodies 11.18.2. Therapeutic Proteins 11.18.3. Vaccines 11.19. Spain Bioengineered Protein Drugs Market Forecast, By Disease Condition 11.19.1. Cancer 11.19.2. Diabetes 11.19.3. Autoimmune Disorder 11.19.4. Infectious Disease 11.19.5. Hematopoiesis 11.19.6. CVD 11.19.7. Neurodegenerative 11.20. Rest of Europe Bioengineered Protein Drugs Market Forecast, By Type 11.20.1. Monoclonal Antibodies 11.20.2. Therapeutic Proteins 11.20.3. Vaccines 11.21. Rest of Europe Bioengineered Protein Drugs Market Forecast, By Disease Condition 11.21.1. Cancer 11.21.2. Diabetes 11.21.3. Autoimmune Disorder 11.21.4. Infectious Disease 11.21.5. Hematopoiesis 11.21.6. CVD 11.21.7. Neurodegenerative 11.22. Europe Bioengineered Protein Drugs Market Attractiveness Analysis 11.22.1. By Type 11.22.2. By Disease Condition 11.23. PEST Analysis 11.24. Key Trend 11.25. Key Development 12. Asia Pacific Bioengineered Protein Drugs Market Analysis 12.1. Key Findings 12.2. Asia Pacific Bioengineered Protein Drugs Market Overview 12.3. Asia Pacific Bioengineered Protein Drugs Market Value Share Analysis, By Type 12.4. Asia Pacific Bioengineered Protein Drugs Market Forecast, By Type 12.4.1. Monoclonal Antibodies 12.4.2. Therapeutic Proteins 12.4.3. Vaccines 12.5. Asia Pacific Bioengineered Protein Drugs Market Value Share Analysis, By Disease Condition 12.6. Asia Pacific Bioengineered Protein Drugs Market Forecast, By Disease Condition 12.6.1. Cancer 12.6.2. Diabetes 12.6.3. Autoimmune Disorder 12.6.4. Infectious Disease 12.6.5. Hematopoiesis 12.6.6. CVD 12.6.7. Neurodegenerative 12.7. Asia Pacific Bioengineered Protein Drugs Market Value Share Analysis, by Country 12.8. Asia Pacific Bioengineered Protein Drugs Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Bioengineered Protein Drugs Market Analysis, by Country 12.10. China Bioengineered Protein Drugs Market Forecast, By Type 12.10.1. Monoclonal Antibodies 12.10.2. Therapeutic Proteins 12.10.3. Vaccines 12.11. China Bioengineered Protein Drugs Market Forecast, By Disease Condition 12.11.1. Cancer 12.11.2. Diabetes 12.11.3. Autoimmune Disorder 12.11.4. Infectious Disease 12.11.5. Hematopoiesis 12.11.6. CVD 12.11.7. Neurodegenerative 12.12. India Bioengineered Protein Drugs Market Forecast, By Type 12.12.1. Monoclonal Antibodies 12.12.2. Therapeutic Proteins 12.12.3. Vaccines 12.13. India Bioengineered Protein Drugs Market Forecast, By Disease Condition 12.13.1. Cancer 12.13.2. Diabetes 12.13.3. Autoimmune Disorder 12.13.4. Infectious Disease 12.13.5. Hematopoiesis 12.13.6. CVD 12.13.7. Neurodegenerative 12.14. Japan Bioengineered Protein Drugs Market Forecast, By Type 12.14.1. Monoclonal Antibodies 12.14.2. Therapeutic Proteins 12.14.3. Vaccines 12.15. Japan Bioengineered Protein Drugs Market Forecast, By Disease Condition 12.15.1. Cancer 12.15.2. Diabetes 12.15.3. Autoimmune Disorder 12.15.4. Infectious Disease 12.15.5. Hematopoiesis 12.15.6. CVD 12.15.7. Neurodegenerative 12.16. ASEAN Bioengineered Protein Drugs Market Forecast, By Type 12.16.1. Monoclonal Antibodies 12.16.2. Therapeutic Proteins 12.16.3. Vaccines 12.17. ASEAN Bioengineered Protein Drugs Market Forecast, By Disease Condition 12.17.1. Cancer 12.17.2. Diabetes 12.17.3. Autoimmune Disorder 12.17.4. Infectious Disease 12.17.5. Hematopoiesis 12.17.6. CVD 12.17.7. Neurodegenerative 12.18. Rest of Asia Pacific Bioengineered Protein Drugs Market Forecast, By Type 12.18.1. Blocks 12.18.2. Panels 12.18.3. Others 12.19. Rest of Asia Pacific Bioengineered Protein Drugs Market Forecast, By Disease Condition 12.19.1. Cancer 12.19.2. Diabetes 12.19.3. Autoimmune Disorder 12.19.4. Infectious Disease 12.19.5. Hematopoiesis 12.19.6. CVD 12.19.7. Neurodegenerative 12.20. Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis 12.20.1. By Type 12.20.2. By Disease Condition 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa Bioengineered Protein Drugs Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Bioengineered Protein Drugs Market Overview 13.3. Middle East & Africa Bioengineered Protein Drugs Market Value Share Analysis, By Type 13.4. Middle East & Africa Bioengineered Protein Drugs Market Forecast, By Type 13.4.1. Monoclonal Antibodies 13.4.2. Therapeutic Proteins 13.4.3. Vaccines 13.5. Middle East & Africa Bioengineered Protein Drugs Market Value Share Analysis, By Disease Condition 13.6. Middle East & Africa Bioengineered Protein Drugs Market Forecast, By Disease Condition 13.6.1. Cancer 13.6.2. Diabetes 13.6.3. Autoimmune Disorder 13.6.4. Infectious Disease 13.6.5. Hematopoiesis 13.6.6. CVD 13.6.7. Neurodegenerative 13.7. Middle East & Africa Bioengineered Protein Drugs Market Value Share Analysis, by Country 13.8. Middle East & Africa Bioengineered Protein Drugs Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Bioengineered Protein Drugs Market Analysis, by Country 13.10. GCC Bioengineered Protein Drugs Market Forecast, By Type 13.10.1. Monoclonal Antibodies 13.10.2. Therapeutic Proteins 13.10.3. Vaccines 13.11. GCC Bioengineered Protein Drugs Market Forecast, By Disease Condition 13.11.1. Cancer 13.11.2. Diabetes 13.11.3. Autoimmune Disorder 13.11.4. Infectious Disease 13.11.5. Hematopoiesis 13.11.6. CVD 13.11.7. Neurodegenerative 13.12. South Africa Bioengineered Protein Drugs Market Forecast, By Type 13.12.1. Monoclonal Antibodies 13.12.2. Therapeutic Proteins 13.12.3. Vaccines 13.13. South Africa Bioengineered Protein Drugs Market Forecast, By Disease Condition 13.13.1. Cancer 13.13.2. Diabetes 13.13.3. Autoimmune Disorder 13.13.4. Infectious Disease 13.13.5. Hematopoiesis 13.13.6. CVD 13.13.7. Neurodegenerative 13.14. Rest of Middle East & Africa Bioengineered Protein Drugs Market Forecast, By Type 13.14.1. Monoclonal Antibodies 13.14.2. Therapeutic Proteins 13.14.3. Vaccines 13.15. Rest of Middle East & Africa Bioengineered Protein Drugs Market Forecast, By Disease Condition 13.15.1. Cancer 13.15.2. Diabetes 13.15.3. Autoimmune Disorder 13.15.4. Infectious Disease 13.15.5. Hematopoiesis 13.15.6. CVD 13.15.7. Neurodegenerative 13.16. Middle East & Africa Bioengineered Protein Drugs Market Attractiveness Analysis 13.16.1. By Type 13.16.2. By Disease Condition 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America Bioengineered Protein Drugs Market Analysis 14.1. Key Findings 14.2. South America Bioengineered Protein Drugs Market Overview 14.3. South America Bioengineered Protein Drugs Market Value Share Analysis, By Type 14.4. South America Bioengineered Protein Drugs Market Forecast, By Type 14.4.1. Monoclonal Antibodies 14.4.2. Therapeutic Proteins 14.4.3. Vaccines 14.5. South America Bioengineered Protein Drugs Market Value Share Analysis, By Disease Condition 14.6. South America Bioengineered Protein Drugs Market Forecast, By Disease Condition 14.6.1. Cancer 14.6.2. Diabetes 14.6.3. Autoimmune Disorder 14.6.4. Infectious Disease 14.6.5. Hematopoiesis 14.6.6. CVD 14.6.7. Neurodegenerative 14.7. South America Bioengineered Protein Drugs Market Value Share Analysis, by Country 14.8. South America Bioengineered Protein Drugs Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil Bioengineered Protein Drugs Market Forecast, By Type 14.9.1. Monoclonal Antibodies 14.9.2. Therapeutic Proteins 14.9.3. Vaccines 14.10. Brazil Bioengineered Protein Drugs Market Forecast, By Disease Condition 14.10.1. Cancer 14.10.2. Diabetes 14.10.3. Autoimmune Disorder 14.10.4. Infectious Disease 14.10.5. Hematopoiesis 14.10.6. CVD 14.10.7. Neurodegenerative 14.11. Mexico Bioengineered Protein Drugs Market Forecast, By Type 14.11.1. Monoclonal Antibodies 14.11.2. Therapeutic Proteins 14.11.3. Vaccines 14.12. Mexico Bioengineered Protein Drugs Market Forecast, By Disease Condition 14.12.1. Cancer 14.12.2. Diabetes 14.12.3. Autoimmune Disorder 14.12.4. Infectious Disease 14.12.5. Hematopoiesis 14.12.6. CVD 14.12.7. Neurodegenerative 14.13. Rest of South America Bioengineered Protein Drugs Market Forecast, By Type 14.13.1. Monoclonal Antibodies 14.13.2. Therapeutic Proteins 14.13.3. Vaccines 14.14. Rest of South America Bioengineered Protein Drugs Market Forecast, By Disease Condition 14.14.1. Cancer 14.14.2. Diabetes 14.14.3. Autoimmune Disorder 14.14.4. Infectious Disease 14.14.5. Hematopoiesis 14.14.6. CVD 14.14.7. Neurodegenerative  14.15. South America Bioengineered Protein Drugs Market Attractiveness Analysis 14.15.1. By Type 14.15.2. By Disease Condition 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Type Launches and Type Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Abbott India Ltd.; 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Type Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. Amgen, Inc.; 15.3.3. Bayer AG; 15.3.4. Biocon Ltd.; 15.3.5. Dr. Reddy’s Laboratories Ltd.; 15.3.6. Eli Lilly and Company; 15.3.7. F. Hoffmann Roche AG; 15.3.8. GlaxoSmithKline PLC; 15.3.9. Johnson & Johnson; 15.3.10. Merck & Co., Inc.; 15.3.11. Novartis International AG; 15.3.12. Panacea Biotec Ltd.; 15.3.13. ProBioGen AG 15.3.14. Reliance Life Sciences Pvt. Ltd 16. Primary Key Insights

About This Report

Report ID 39151
Category Healthcare
Published Date Dec 2019
Updated Date Nov 2020
Contact Us